The Question Behind Every Purchase
When a hospital buys three hundred beds, they are not really buying beds. They are buying the assurance that a factory two thousand kilometres away, which they will never visit, has done its job properly — and will keep doing it for the next five years of repeat orders and spare parts supply.
That assurance has to come from somewhere. In a well-structured trade relationship, it comes from the trading partner having done the work the buyer cannot practically do themselves.
Vetting medical equipment manufacturing partners is the least visible part of the business and one of the most consequential. This article describes how Opus Hestia approaches it.
Why This Matters More in Medical Equipment
In most product categories, a bad supplier decision costs money. In medical equipment it can cost considerably more.
A bed side rail that fails can injure a patient. An examination table that collapses creates liability across the whole chain. A batch of equipment with a latent electrical fault may need recalling from wards across several countries — which is only possible if traceability exists. And a factory that quietly substitutes materials to protect margin produces a fleet of equipment that ages badly and simultaneously, three years after installation.
Institutional buyers know this, which is why they increasingly ask not only about the product but about the factory behind it. A supplier who cannot answer has effectively admitted that nobody has checked.
Stage One: Capability Screening
The first stage removes candidates who cannot meet baseline requirements, without consuming audit resources.
Legal and corporate standing. Registration, ownership structure, operating history, and any regulatory or legal issues on record. Trading history matters — a factory that has operated consistently through economic cycles has demonstrated something a new entrant cannot.
Financial stability. This is frequently underweighted. A factory under financial pressure cuts material specifications, delays supplier payments — which disrupts component supply — and may not survive the warranty period of equipment it has already sold. Reviewing accounts and payment behaviour is a quality control measure, not merely a credit check.
Certification. ISO 13485 as the medical device quality baseline, ISO 9001, and any product-specific approvals. Certificates are checked for accrediting body, validity, and — critically — whether the scope actually covers the relevant product and activities. Scope mismatch is the most common problem found at this stage.
Product and technical fit. Existing product range, engineering capability, in-house versus outsourced processes, and design capability for customisation.
Capacity. Realistic monthly output, existing commitments, workforce size and stability, and equipment condition.
Export experience. Which markets they have supplied, what documentation they routinely produce, and whether they understand the requirements of regulated destinations.
Most candidates are eliminated here, usually on scope mismatch, insufficient capacity, or absent export documentation capability.
Stage Two: Documentation Review
Surviving candidates provide a substantial evidence pack:
- Quality manual and key documented procedures
- Recent internal and external audit reports, including non-conformities raised and how they were closed
- Product technical files, drawings and specifications
- Test reports from recognised laboratories
- Material certificates for principal inputs
- Sub-supplier list and qualification records
- Complaint records and corrective action history
- Production and inspection records for recent batches
- Employment, wage and health-and-safety documentation
The most informative documents are the ones companies expect least to be examined. Complaint and corrective action records are particularly revealing. A factory with no recorded complaints is not a factory without problems; it is a factory that does not record them. What matters is whether issues are investigated, root causes identified and corrections verified as effective.
Non-conformity closure records from previous audits tell the same story. Findings that recur year after year indicate a system that documents problems without solving them.
Stage Three: The Factory Audit
Documentation describes intention. The audit establishes reality.
Facility condition. Building fabric, lighting, ventilation, cleanliness, organisation, material flow and segregation of incoming, in-process and finished goods. A disorganised factory produces inconsistent product; the correlation is close to absolute.
Equipment. Machinery condition, maintenance records, calibration status of measuring and test equipment. Uncalibrated instruments mean unverifiable quality claims.
Incoming inspection. How raw materials are received, verified and released. Is steel gauge checked, or accepted on the supplier’s word? Are material certificates retained? Where does rejected material go?
Production process. Watching actual production is more informative than any document. Are work instructions available at the workstation and actually used? Are operators trained for the task they are performing? Are in-process checks conducted or merely recorded? Is welding consistent? Is the coating line properly controlled, with the pre-treatment stages functioning rather than bypassed?
Coating line inspection deserves specific attention in hospital furniture, because pre-treatment is the most common and least visible shortcut in the industry. Verifying that tanks are maintained, chemistry is monitored and dwell times are observed tells you more about long-term product durability than almost anything else on the floor.
Final inspection and testing. What is checked, against what criteria, by whom, and what happens to failures. Is the test equipment functional and calibrated?
Traceability. Can a finished unit be traced back to its production batch and material certificates? Ask them to demonstrate it with a randomly selected unit rather than describe the system.
Storage and dispatch. Finished goods protection, packaging quality, environmental conditions.
Workforce conditions. Health and safety practices, protective equipment, working hours and wage records. Increasingly a formal requirement in institutional procurement, and independently correlated with production quality.
Conversations with staff. Supervisors, quality personnel and operators. Their fluency about their own processes reveals whether the system is operational or ceremonial.
Stage Four: Sample and Trial Production
Audits assess systems. Samples assess output.
Sample units are produced to the agreed specification and evaluated against it in detail — dimensions, weight, materials, finish quality, mechanical operation. Independent laboratory testing verifies load capacity, coating adhesion, salt spray resistance and electrical safety where applicable.
Destructive examination of at least one unit: cut sections to verify steel gauge, examine weld penetration, check coating thickness, inspect internal construction that finished-goods inspection cannot reach.
Trial production of a limited batch then tests consistency, which is the real question. One excellent sample proves capability. A consistent batch proves process control. Variation across a trial batch is a reliable predictor of variation across a container.
Stage Five: Commercial and Contractual Structure
Vetting concludes with agreements that make quality enforceable rather than aspirational.
Specifications are annexed in full detail — materials, components, tolerances, finishes, named component brands — so that “equivalent substitution” cannot be argued after the fact. Quality standards and acceptance criteria are defined objectively. Inspection rights, including unannounced access, are written in. Non-conforming goods procedures, delivery commitments and remedies, warranty obligations, spare parts supply commitments and change control requirements are all specified.
Change control matters more than most buyers realise. A factory that changes a component supplier without notification has changed the product, whatever the drawing still says. Contractual notification requirements make that visible.
Stage Six: Ongoing Monitoring
Qualification is a beginning, not a conclusion. Factories change — ownership, management, key staff, sub-suppliers, financial position.
Continuous monitoring includes pre-shipment inspection of every consignment, periodic re-audit, certification currency tracking, delivery and defect performance metrics, field failure analysis fed back to production, and periodic financial review.
Field failure data is the most valuable input of all. Knowing which components fail, in which conditions, after how long, allows specifications to be improved before the next production run. A manufacturing partner who never receives this information cannot improve; one who receives it and acts on it becomes progressively better.
What This Means for Buyers
When purchasing through a trade partner, ask what their qualification process involves:
- How did you select this manufacturing partner, and what did the process involve?
- When was the factory last audited, and by whom?
- What findings were raised, and how were they closed?
- Can we see the factory, physically or remotely?
- What is inspected before shipment, and can we witness it?
- How is a specification change controlled and communicated?
- What is the current defect rate, and how has it moved?
Specific, detailed answers indicate genuine oversight. General reassurance indicates a broker.
Closing Thought
Vetting manufacturing partners is slow, detailed and largely invisible to the customer. It happens in factories, in audit reports, in cut-section samples and in trial batches that nobody outside the process ever sees.
But it is precisely this work that determines whether the equipment arriving at a hospital in three months performs as specified — and whether the equipment arriving in three years performs the same way.
For buyers, the practical question is simple: has someone done this work on your behalf, and can they prove it?